Abstract: The present invention relates to inhibiting TNF in patients having rheumatoid arthritis, psoriatic arthritis or ankylosing spondilitis, by administering anti-TNF antibodies comprising the heavy chain variable region of SEQ ID NO: 7 and the light chain variable region of SEQ ID NO:8, specific for at least one human tumor necrosis factor alpha (TNF) protein or fragment thereof.
Type:
Grant
Filed:
November 11, 2008
Date of Patent:
October 26, 2010
Assignee:
Centocor, Inc.
Inventors:
George Heavner, David M. Knight, Jill Giles-Komar, Bernard Scallon, David Shealy
Abstract: The present invention relates to inhibiting TNF in patients having rheumatoid arthritis, psoriatic arthritis or ankylosing spondilitis, by administering anti-TNF antibodies comprising the heavy chain variable region of SEQ ID NO: 7 and the light chain variable region of SEQ ID NO:8, specific for at least one human tumor necrosis factor alpha (TNF) protein or fragment thereof.
Type:
Grant
Filed:
November 13, 2008
Date of Patent:
October 19, 2010
Assignee:
Centocor, Inc.
Inventors:
George Heavner, David M. Knight, Jill Giles-Komar, Bernard Scallon, David Shealy
Abstract: The invention relates to a method of directing selection of biological therapeutic molecules to specific functional domains of the target biologic molecule. Selection is directed by the use of closely related molecules, where one is a decoy and the other contains the targeted domain or epitope. The invention is based on the use of physical data, which may be combined with derived data, to ascertain that the decoy and the target differ only in the specific functional domain or epitope where the binding will be directed.
Type:
Grant
Filed:
April 22, 2005
Date of Patent:
September 7, 2010
Assignee:
Centocor, Inc.
Inventors:
Karyn O'Neil, Raymond Sweet, George Heavner
Abstract: The present invention provides CDR-grated antibodies against human tissue factor that retain the high binding affinity of rodent monoclonal antibodies against tissue factor but have reduced immunogenicity. The present humanized antibodies are potent anticoagulants and are thus useful in the treatment and prophylaxis of human thrombotic disease. The invention also provides methods of making the CFR-grafted antibodies and pharmaceutical compositions for the attenuation or prevention of coagulation.
Type:
Grant
Filed:
October 29, 2007
Date of Patent:
August 17, 2010
Assignee:
Centocor, Inc.
Inventors:
Linda K. Joliffe, Robert A. Zivin, Virginia L. Pulito
Abstract: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-? (TNF?) and are useful in vivo diagnosis and therapy of a number of TNF?-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.
Type:
Grant
Filed:
December 7, 2007
Date of Patent:
June 29, 2010
Assignees:
Centocor, Inc., New York University
Inventors:
Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight, Scott Siegel
Abstract: Antibody expression vectors and plasmids can incorporate various antibody gene portions for transcription of the antibody DNA and expression of the antibody in an appropriate host cell. The expression vectors and plasmids have restriction enzyme sites that facilitate ligation of antibody-encoding DNA into the vectors. The vectors incorporate enhancer and promoter sequences that can be varied to interact with transcription factors in the host cell and thereby control transcription of the antibody-encoding DNA. A kit can incorporate these vectors and plasmids.
Type:
Grant
Filed:
December 21, 2005
Date of Patent:
June 15, 2010
Assignee:
Centocor, Inc.
Inventors:
Jin Lu, Thomas Nesspor, Bernard Scallon, Linda Snyder
Abstract: Toll Like Receptor 3 (TLR3) modulators, such as antibodies, polynucleotides encoding TLR3 antibodies or fragments thereof, and methods of making and using the foregoing are disclosed.
Type:
Grant
Filed:
October 27, 2006
Date of Patent:
May 18, 2010
Assignee:
Centocor, Inc.
Inventors:
Karen E. Duffy, Chong C. Huang, Roberta Lamb, Mouhamadou L. Mbow, Robert T. Sarisky, Lani San Mateo
Abstract: Isolated polynucleotides encoding Cynomolgus monkey prostate specific antigen and polypeptides obtainable from the polynucleotides and uses are disclosed.
Abstract: The present invention relates to at least one novel human EPO mimetic hinge core mimetibody or specified portion or variant, including isolated nucleic acids that encode at least one EPO mimetic hinge core mimetibody or specified portion or variant, EPO mimetic hinge core mimetibody or specified portion or variants, vectors, host cells, and methods of making and using thereof, for preventing or treating glucose intolerance and/or renal disease associated anemia, including therapeutic compositions, methods and devices.
Abstract: Human Bone Morphogenic Protein 7 (hBMP-7) variant peptide chains, nucleic acids encoding these peptide chains, and methods of making and using the foregoing are disclosed.
Type:
Grant
Filed:
June 8, 2007
Date of Patent:
February 9, 2010
Assignee:
Centocor, Inc.
Inventors:
Bernard Amegadzie, Mark Cunningham, Haimanti Dorai, Jeffrey Luo, Juliane Mills, Bethany Swencki-Underwood
Abstract: The invention provides a genetic screening method for identifying a transfected cell expressing the polypeptide of interest. The methods allows for high throughput screening of recombinant cells for elevated levels of expression of the polypeptide of interest using methylcellulose comprising fluorescent protein A or G to improve detection and cloning. The invention also provides capture media, formulations and methods of making and using thereof.
Type:
Application
Filed:
March 28, 2008
Publication date:
February 4, 2010
Applicant:
CENTOCOR, INC.
Inventors:
Edward Appelbaum, Susanne Corisdeo, Subiney Ganguly, Dennis M. Kraichely, Sunil Mehta, Gordon Moore, Richard Siegel
Abstract: The present invention relates to at least one improved human GLP-1 mimetibody or specified portion or variant, including isolated nucleic acids that encode at least one GLP-1 mimetibody or specified portion or variant, GLP-1 mimetibody or specified portion or variants, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.
Abstract: The present invention relates to at least one novel chimeric, humanized or CDR-grafted anti-IL-6 antibodies derived from the murine CLB-8 antibody, including isolated nucleic acids that encode at least one such anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.
Type:
Grant
Filed:
August 1, 2007
Date of Patent:
November 3, 2009
Assignee:
Centocor, Inc.
Inventors:
Jill Giles-Komar, David Knight, David Peritt, Mohit Trikha
Abstract: Isolated anti-tissue factor antibodies, immunoglobulins, cleavage products and other specified portions and variants thereof having enhanced ADCC activity, as well as anti-tissue factor antibody compositions, encoding or complementary nucleic acids, vectors, host cells, compositions, formulations, devices, transgenic animals, transgenic plants, and methods of making and using thereof. The antibodies of the invention bind human tissue factor and demonstrate enhanced ADCC activity. Accordingly, the antibodies can be used in a variety of methods for diagnosing, treating, and/or preventing diseases involving tissue factor, where enhanced ADCC activity is desirable such as cancer.
Type:
Grant
Filed:
December 13, 2004
Date of Patent:
October 20, 2009
Assignee:
Centocor, Inc.
Inventors:
G. Mark Anderson, Bernard Scallon, Michael Naso, Ann Cai, Cam Ngo
Abstract: Chemically defined media compositions for the culture of eukaryotic cells are disclosed. The compositions are useful for eukaryotic cell culture in perfusion bioreactors and other vessels.
Type:
Grant
Filed:
October 27, 2005
Date of Patent:
October 6, 2009
Assignee:
Centocor, Inc.
Inventors:
David Epstein, Roger Monsell, Joseph Horwitz, Susan Lenk, Sadettin Ozturk, Christopher Marsh
Abstract: The present invention relates to at least one novel anti-alpha-V subunit antibodies, including isolated nucleic acids that encode at least one anti-alpha-V subunit antibody, alpha-V subunit, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.
Type:
Grant
Filed:
November 13, 2006
Date of Patent:
June 23, 2009
Assignee:
Centocor, Inc.
Inventors:
Jill Giles-Komar, Linda Snyder, Mohit Trikha, Marian T. Nakada
Abstract: The present invention provides CDR-grated antibodies against human tissue factor that retain the high binding affinity of rodent monoclonal antibodies against tissue factor but have reduced immunogenicity. The present humanized antibodies are potent anticoagulants and are thus useful in the treatment and prophylaxis of human thrombotic disease. The invention also provides methods of making the CFR-grafted antibodies and pharmaceutical compositions for the attenuation or prevention of coagulation.
Type:
Grant
Filed:
November 1, 2006
Date of Patent:
June 9, 2009
Assignee:
Centocor, Inc.
Inventors:
Linda K. Joliffe, Robert A. Zivin, Virginia L. Pulito
Abstract: The present invention relates to at least one novel anti-TNF antibodies, including isolated nucleic acids that encode at least one anti-TNF antibody, TNF, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.
Type:
Grant
Filed:
July 13, 2005
Date of Patent:
April 21, 2009
Assignee:
Centocor, Inc.
Inventors:
George Heavner, David M. Knight, Jill Giles-Komar, Bernard Scallon, David Shealy
Abstract: A tissue factor antibody which binds to non-human tissue factor and is useful as a surrogate in preclinical testing where the human therapeutic tissue factor candidate antibody does not interact with the homolog target protein in a manner that would provide meaningful information about treatment efficacy or safety.